mounting instructions ms 20, ms 21 ms 25, ms 26 version mo, mk
ms - 32651
-
Upload
ale-thornton -
Category
Documents
-
view
217 -
download
0
Transcript of ms - 32651
-
8/2/2019 ms - 32651
1/28
1
Clinical Correlates of Increased Levels of Autoantibodies
in Chagas Heart Disease
Andre Talvani, Manoel O.C. Rocha
, Antonio L. Ribeiro
, Enri Borda
,
Leonor Sterin-Borda
& Mauro M Teixeira.
Departamento de Bioqumica e Imunologia, Instituto de Cincias Biolgicas and, Ps-
Graduao em Medicina Tropical, Departamento de Clnica Mdica, Faculdade de Medicina,
UFMG,Belo Horizonte, Brasil andPharmacology Unit, School of Dentistry, University of
Buenos Aires, Buenos Aires, Argentina.
Short title: Anti-M2 autoantibodies in Chagas Heart Disease
-
8/2/2019 ms - 32651
2/28
2
Footnote page:
(1) Informed consent was obtained from all patients and non-infected individuals.
Human experimental guidelines of the Brazilian Ministry of Health were followed in the
conduct of the experiments described here. The authors have not commercial or other
association that may pose a conflict of interest.
(2) This investigation received financial support from FAPEMIG, the UNDP/World
Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR-
WHO A970728) and Conselho Nacional de Desenvolvimento Cientfico e Tecnolgico
(CNPq-Brazil) and National Research Council (CONICET) of Argentina, TDR-WHO
A20771 and University of Buenos Aires (UBACYT), Buenos Aires, Argentina.
(3) Address for correspondence and reprints request
Mauro M Teixeira, M.D.
Departamento de Bioqumica e Imunologia
Instituto de Cincias Biolgicas
Universidade Federal de Minas Gerais
Av. Antnio Carlos, 6627 - Pampulha
31270-901 BELO HORIZONTE MG BRASIL
Phone # 55 31 3499 2651 (direct line)
Fax # 55 31 3441 5963e-mail: [email protected]
Alternative contact:
Dr Leonor Sterin-Borda ([email protected]).
-
8/2/2019 ms - 32651
3/28
3
Abstract
Background: Anti-neurotransmitter receptor autoantibodies are found in the serum of
chagasic patients and may play a role in the pathophysiology of the disease. In the present
study, we investigated the presence of autoantibodies and their correlation with the
severity of chronic chagasic cardiomyopathy (CCC). Methods: Anti-M2 cholinergic and
anti-1 adrenergic autoantibodies were measured in sera of non-infected subjects and
chagasic patients with the various clinical forms of the disease using ELISA. Results:
The optical density (OD) and the frequency of anti-M2 and anti-1 antibodies were higher
in chagasic patients than in non-infected subjects. The levels of anti-M2 antibodies were
lower in patients with the indeterminate form than patients with CCC, levels of both
antibodies were similar in patients with CCC, regardless of severity. This is consistent
with lack of correlation between levels of autoantibodies and various parameters of
ventricular dysfunction. Patients with apical lesion, with exercise-induced ventricular
arrhythmias, or those with chronotropic insufficiency had higher levels of anti-M2
autoantibodies. Conclusion: The levels of anti-neurotransmitter autoantibodies in serum
of patients with Chagas heart disease seemed not to correlate with the severity of the left
ventricular dysfunction. Nevertheless, the levels of anti-M2 autoantibodies are increased
in patients in which apical aneurysm, ventricular arrhythmias and chronotropic
incompetence, suggesting that anti-M2 cholinergic autoantibodies may play a role in the
pathogenesis of chagasic cardiac dysautonomia.
Key Words: chagas cardiomyopathy chagas disease neurotransmitter receptor
antibodies anti-adrenergic antibodies anti-cholinergic antibodies
-
8/2/2019 ms - 32651
4/28
4
Introduction
In Latin America, chronic chagasic cardiomyopathy (CCC) affects around 30% of
individuals infected with the protozoan parasite Trypanosoma cruzi (T. cruzi). In a
significant proportion of the latter patients, severe heart disease occurs and is frequently
the cause of death. There are several hypotheses that try to explain the pathogenesis of
severe heart disease in infected individuals, including the role of parasite persistence
(1,2), autoimmune events (3-6) and microvascular dysfunction (7).
Chronic chagasic cardiomyopathy is characterized mainly by a dilated
cardiomyopathy complicated by frequent and complex ventricular arrhythmias and/or
conduction defects (8). Autonomic dysfunction occurs early in the course of the disease
and may associate with worse prognosis (9-12). It has been argued that the blockade of
neurotransmitter receptors by anti-receptor antibodies contributes to the autonomic
dysfunction and worse clinical evolution (12-14). Although a strong association between
circulating antipeptide M2 muscarinic acetylcholine receptor (mAChR) autoantibodies
and the presence of patients' low heart rate variability index, bradycardia and cardiac or
esophageal autonomic dysfunction in chronic chagasic patients was verified (15), it is not
known whether the presence and/or titer of anti-receptor antibodies correlate with CCC
severity.
Here, the presence and levels of anti-adrenergic (1) and anti-muscarinic (M2)
receptor antibodies were evaluated in serum of a group of 58 individuals. We also
investigated the correlation between the titers of autoantibodies and the following aspects
of clinical CCC manifestations: left ventricular systolic function and response to effort.
-
8/2/2019 ms - 32651
5/28
5
Methods
Study population
We performed this initial study with 6 healthy individuals and 52 chagasic
patients with different clinical forms of the disease. All individuals were recruited at the
Referral Center for Training on Infectious and Parasitic Diseases (CTR-DIP) at Hospital
das Clinicas, Universidade Federal de Minas Gerais (UFMG) and underwent a complete
clinical examination and performed the following laboratory workup: full blood count,
free T4, TSH, glucose, potassium, creatinine, blood urea nitrogen, electrocardiogram
(ECG), chest X-Ray, a 24 hour Holter examination, echoDopplercardiography (ECHO)
and a treadmill exercise test. Patients with hypertension, diabetes, thyroid or renal
disturbances or any other cardiac or systemic diseases and those using steroidal drugs
were excluded from this study, as these conditions could prevent adequate interpretation
of cardiac disease severity on immune parameters. The study received ethical clearance
from the Ethics Review Board of Universidade Federal de Minas Gerais.
Chagasic patients were also categorized into groups according to the degree of
heart dysfunction, as previously described (8). Briefly, patients with indeterminate form
(IND) (n=8) or chronic chagasic cardiomyopathy grade I (CCC I) (n=8) were those with
normal ECG and radiological studies or with only minor alterations in their ECHO (e.g.
regional contraction defects), respectively. Patients classified as CCC II/III (n=7) were
those with minor or moderate ECG alterations, including block of the anterosuperior
division of the left branch, right bundle branch block or uniform ventricular premature
contractions. Patients classified as CCC IV (n=15) were those manifesting severe
conduction defects (e.g. left bundle branch block, left anterior divisional block with right
-
8/2/2019 ms - 32651
6/28
6
bundle branch block or total atrioventricular block) or complex ventricular arrhythmias
(complex ventricular premature beats, non-sustained or sustained ventricular
tachycardia). Finally, patients classified as CCC V were those with ventricular
enlargement, as observed on the ECHO, irrespective of the presence or not of
arrhythmias or conduction defects (8). The control group was formed by non-infected
(NI) healthy individuals (Table 1).
A maximal stress test was performed according to the standard Bruce protocol.
Chronotropic insufficiency was arbitrarily defined as the inability to achieve at least 85%
of the predicted heart rate according to Astrands formula (220-age) at peak exercise (16).
Patients with exercise-induced arrhythmias were those who presented non-sustained
ventricular tachycardia or increase ventricular premature beats number (NVPB) or
complexity (polimorphic or repetitive forms) clearly related to the exercise. Patients
underwent ECHO with color flow using an ATL Philips HDI 5000 apparatus operated by
an experienced echocardiographer, blinded to the clinical status of the patients.
Segmental contractility was evaluated according to the method described by American
Society of Echocardiography (17) and typical apical lesions in the left ventricle wall were
recognized. The left ventricular ejection fraction (LVEF) was obtained by Simpson's
method using the software provided with the equipment.
Measurement of antibodies against anti-M2 cholinergic and anti-1 adrenergic receptors
Serum samples were obtained by conventional venipuncture, centrifuged and
stored at -80oC until used in an immunoassay (ELISA) with M2 synthetic cholinergic
peptide (18) and 1 adrenergic synthetic peptide (14) as coating antigens, as previously
-
8/2/2019 ms - 32651
7/28
7
described (19). The samples were assayed in parallel at a 1/50 dilution and optical
density (OD) values were measured with an ELISA reader (Uniskan Laboratory System).
This antibody dilution was found to be optimal to separate chronic chagasic
cardiomyopathy patients from control indeterminate form of Chagas heart disease.
Statistical analysis
Data are expressed as means SEM or median and interquartile range. Analysis
was performed using the computer program GraphPrism (GraphPad, San Diego, CA,
USA). Comparison between groups carried was out by using Analysis of Variance
(ANOVA) followed by Student-Newman-Keulss post test (parametric distribution) or
Kruskal Wallis followed by Dunns post test (non-parametric distribution). For
association between variables, data were analyzed using linear regression analysis and
Spearmans rank correlation test. Probability values were considered significant when
p
-
8/2/2019 ms - 32651
8/28
8
Results
There was no significant difference in the age distribution of non-infected
individuals and chagasic patients (Table 1). In agreement with the clinical parameters
used to classify the group, patients with CCC V had lower left ventricle ejection fraction
and greater diastolic diameter in comparison with patients with the other degrees of CCC.
There was great variation in the number of ventricular premature beats in 24 hour and
patients with CCC II/III or worse had greater number of premature beats than those with
IND form or CCC 1 (Table 1).
The distribution of anti-M2 cholinergic and anti-1 adrenergic autoantibodies
detected by ELISA is shown in Table 2. It can be seen that the frequency of anti-M 2
cholinergic autoantibody was higher in CCC patients (mean values: 86.3%) than in the
IND form (mean values 37.5%) of Chagas disease. The non-infected individuals were
negative in the study system. When the distribution of anti-1 adrenergic autoantibodies
was evaluated no differences in the frequency between CCC patients (mean value 67.2%)
and IND (mean value 77.1%) was observed. Table 2 also shows the distribution of both
autoantibodies in the different degrees of CCC and it can be appreciated that no
differences existed between the different degrees of CCC.
Figure 1 shows the levels of cholinergic (M2) and adrenergic (1) autoantibodies
in serum from non-chagasic and chagasic individuals. It can be seen that chagasic
patients presented greater levels of both autoantibodies. However, when chagasic patients
were grouped according to disease severity (8), there was no difference in the OD values
of both M2 and 1 autoantibodies among the different clinical groups (Figure 1). The lack
of correlation between levels of autoantibodies and disease severity is further re-enforced
-
8/2/2019 ms - 32651
9/28
9
when the levels of antibodies and clinical parameters of ventricular dysfunction were
compared (Table 3).
Interestingly, patients presenting apical lesion in the left ventricle had higher
levels of anti-M2 antibodies (Figure 2), but not anti-1 antibodies than patients without
apical lesion (Figure 2). Patients that presented ventricular arrhythmias during or
immediately after exercise had higher levels of anti-M2 antibodies, but not anti-1
antibodies than patients who did not present exercise-induced arrhythmias (Figure 3A).
Moreover, the levels of anti-M2 antibodies were higher in patients with than those
without chronotropic insufficiency (Figure 3B). The levels of anti-1 antibodies were
similar in patients with or without chronotropic incompetence (Figure 3B).
-
8/2/2019 ms - 32651
10/28
10
Discussion
Global systolic left ventricular dysfunction is the strongest predictor of morbidity
and mortality during Chagas heart disease (20,21). It has been argued that an
autoimmune response against antigens present in heart tissue may favor the development
of the more severe forms of Chagas cardiomyopathy. Antibodies against adrenergic and
cholinergic receptors are among the many autoantibodies that have been described in
Chagas disease. For example, antibodies against 1-adrenoceptores and M2 mAChR have
been found in the sera of patients and experimental animals with Chagas disease
(5,12,14). These antibodies may induce acute functional alterations of isolated hearts
from experimental animals (e.g. enhance or decrease contractility) and may also interact
with the respective receptor and induce sequestration and endocytosis of the receptor (22-
25). Thus, it is clear that chagasic patients have anti-M2 or anti-1 receptor antibodies and
that the binding of these autoantibodies to the receptors may have functional
consequences. However, it is unclear whether the autoantibodies have a role in the
pathogenesis of Chagas disease and/or reflect structural damage to the heart. In regard to
the latter possibility, anti-M2 and anti-1 antibodies are also found in serum of patients
with other forms of heart disease (12,26-28).
Our results showed that individuals with chronic chagasic cardiomyopathy had
elevated levels of both adrenergic and cholinergic autoantibodies when compared with
non-infected controls. The frequency of anti-M2 autoantibody was higher in CCC than in
IND form of the disease, suggesting that the anti-M2 autoantibody could be used as an
early marker of evolution in Chagas cardiomyopathy. However, levels of this
autoantibody were not able to differentiate the various forms of Chagas heart disease.
-
8/2/2019 ms - 32651
11/28
11
This was reflected in the lack of correlation between levels of autoantibodies and the left
ventricular ejection fraction or the left ventricular end-diastolic diameter, both important
parameters of left ventricular dysfunction. Thus, although the presence of antibodies is
associated with the presence of Chagas heart disease, there seems to be no association
between the levels of antibodies and the degree of left ventricular function. The latter
results suggest that left ventricular dysfunction appears not to be the cause of augmented
serum levels of anti-M2 and anti-1 antibodies in Chagas disease and, on the other hand,
the antibodies may not have a direct role in the pathogenesis of the left ventricular
dysfunction that accompanies the most severe cases of Chagas disease. Alternatively, it is
possible that the titers of circulating autoantibodies do not reflect the amount of those
fixed on myocardium neurotransmitter receptors.
Despite the apparent lack of association between left ventricular function and
level of autoantibodies, there were significant associations between the level of anti-M2
antibodies and the presence of apical lesion, exercise-induced arrhythmia and the
chronotropic response to exercise. None of the latter parameters were associated with the
level of anti-1 receptor antibodies. Segmental changes of myocardial contractility,
especially of the apex and the postero-inferior wall of the left ventricle, are common in
Chagas heart disease (29). The apical aneurysm is the most peculiar finding in Chagas
disease, although also observed in other types of heart disease, with thinning and deficit
preferentially localized on the apex of the left ventricle, with or without thrombus
(30,31). In the endemic area, aneurysms of the left ventricle were diagnosed in 18.8%
patients and were related to symptoms, specially palpitations, ECG abnormalities, such as
ventricular extra-systoles and conduction abnormalities, and impairment of the
-
8/2/2019 ms - 32651
12/28
12
ventricular function (32). Moreover, left ventricular aneurysms are associated with the
development of malignant sustained ventricular arrhythmias (33) and are independent
predictors of death (34). The pathogenetic hypothesis for the development of the left
ventricular aneurysms includes mechanical, electrical, inflammatory, ischemic and
autonomic mechanisms. Our results showed that patients with apical aneurysm had
higher levels of anti-M2 receptor antibodies than patients without the lesion, although the
exact meaning of this finding remains unknown.
The occurrence of ventricular arrhythmia during exercise testing is related with
increased mortality due to Chagas disease (35). Here, we found that there was an
association between the levels of anti-M2 receptor antibodies and the presence of effort-
induced ventricular arrhythmias, as demonstrated by exercise testing. Experimental
studies have shown that activation of muscarinic receptors by anti-receptor antibodies
may induce their internalization and, consequently, loss of parasympathetic function (12).
The loss of parasympathetic tonus could then potentially facilitate the occurrence of
arrhythmias, especially during exercise.
Indeed, the level of anti-M2, but not anti-1, receptor antibodies was greater in
patients in whom the presence of chronotropic incompetence during exercise testing was
detected. Preserved autonomic modulation is a major determinant of physiological heart
rate response to exercise. Chronotropic incompetence, which is independent of left
ventricular dysfunction in Chagas disease, may be considered a manifestation of
autonomic dysfunction (11).The latter findings may be secondary to chronic muscarinic
receptor stimulation by the antibodies and resulting receptor desensitization and
impairment of parasympathetic function. This is consistent with our previous results
-
8/2/2019 ms - 32651
13/28
13
demonstrating the presence of parasympathetic impairment in the absence of heart failure
in Chagas disease (11).
In conclusion, we showed that the levels of anti-M2 or anti-1 receptors in serum
of patients with Chagas disease seemed not to correlate with the severity of the left
ventricular dysfunction. Nevertheless, the levels of anti-M2 antibodies were greater in
patients with apical aneurysm, in those with exercise-induced ventricular arrhythmias and
were related to the presence of chronotropic incompetence. Overall, these results point to
an important role of anti-M2 receptor antibodies in the pathogenesis of the dysautonomia
frequently observed in Chagas disease.
-
8/2/2019 ms - 32651
14/28
14
Acknowledgements
This investigation received financial support from FAPEMIG, the UNDP/World
Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR-
WHO A970728 and A20771) and Conselho Nacional de Desenvolvimento Cientfico e
Tecnolgico (CNPq-Brazil) and National Research Council (CONICET) of Argentina,
and University of Buenos Aires (UBACYT), Buenos Aires, Argentina.
-
8/2/2019 ms - 32651
15/28
15
References
1. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol. 2001;
31:550-554.
2. Teixeira, M.M., Gazzinelli, R.T., Silva, J.S. Chemokines, inflammation and
Trypanosoma cruzi infection. Trends Parasitol. 2002;18: 262-5.
3. Soares MB, Pontes-De-Carvalho L, Ribeiro-Dos-Santos R. The pathogenesis of Chagas'
disease: when autoimmune and parasite-specific immune responses meet. An Acad Bras
Cienc 2001; 73: 547-59.
4. Abel LCJ, Rizzo LV, Ianni B, Albuquerque F, Bacal F, Carrara D, Bocchi EA, Teixeira
HC, Mady C, Kalil J, Cunha-Neto E. Chronic Chagasdisease cardiomyopathy patients
display an increased IFN-g response to Trypanosoma cruzi infection. J. Autoimmunity
2001; 17:99-108.
5. Borda E, Cossio P, de la Vega M, Arana R, Sterin-Borda L. Circulatin IgG in
Chagasdisease which binds to h-adrenoreceptores of myocardium and modulate their
activity. Clin Exp Immunol 1984; 57:670-86.
6. Leon JS, Engman DM. The significance of autoimmunity in the pathogenesis of Chagas
heart disease. Front Biosci. 2003; 8:315-322.
7. Petkova SB, Huang H, Factor SM, Pestell RG, Bouzahzah B, Jelicks LA, Weiss LM,
Douglas SA, Wittner M, Tanowitz HB. The role of endothelin in the pathogenesis of
Chagasdisease. Intern J. Parasitol. 2001; 31: 499-511.
-
8/2/2019 ms - 32651
16/28
16
8. Rocha MOC, Ribeiro AL, Teixeira MM. Clinical Management of chronic Chagas
cardiomyopathy.. Front Biosc. 2003; 8:E44-54.
9. Iosa D, Dequatro V, De-Ping-Lee D, Elkayan V, Caieiro T. Plasma norepinephrine in
chagasic cardiomyopathy: a marker of progressive dysautonomia. Am Heart J. 1989; 117:
882-887.
10. Iosa D, Dequatro V, De-Ping-Lee D, Elkayan V, Palmero H. Pathogenesis of cardiac
neuropathy in Chagas Disease and the role of autonomic nervous system. J. Autonomic
Nervous System. 1990; 30:583-588.
11. Ribeiro AL, Moraes RS, Ribeiro JP, Ferlin EL, Torres RM, Oliveira E, Rocha MO.
Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas
disease. Am Heart J. 2001; 141:260-265.
12. Borda ES & Sterin-Borda L. Antiadrenergic and muscarinic receptor antibodies in
Chagas cardiomyopathy. Intern J Cardiol 1996; 54:149-56.
13. Joensen L, Borda E, Kaohout T, Perry S, Garcia G, Sterin-Borda L. T.cruzi antigen that
interacts with the beta 1 adrenergic receptor and modifies myocardial contractile activity.
Mol Biochem Parasitol 2003; 127:169-177.
14. Sterin-Borda L, Gorelik G, Postan M, Gonzalez Cappa S, Borda E.. Alterations in cardiac
beta-adrenergic receptors in chagasic mice and their association with circulating beta-
adrenoceptor-related autoantibodies. Cardiovas Res 1999; 41:116-25.
-
8/2/2019 ms - 32651
17/28
17
15. Sterin-Borda L, Borda E. Role of neurotransmitter autoantibodies in the pathogenesis of
chagasic peripheral dysautonomia. Ann N Y Acad Sci. 2000; 917: 273-80.
16. Fei L, Keeling PJ, Sadoul N, Copie X, Malik M, McKenna WJ, Camm AJ. Decreased
heart rate variability in patients with congestive heart failure and chronotropic
incompetence. Pacing Clin Electrophysiol. 1996; 19:477-83.
17. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell
H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left
ventricle by two-dimensional echocardiography. American Society of Echocardiography
Committee on Standards, Subcommittee on Quantitation of Two-Dimensional
Echocardiograms. J Am Soc Echocardiogr1989;2:358-367.
18. Sterin-Borda L, Joensen L, Bayo Hanza C, Esteva M, Borda E. Therapeutic used of
muscarinic acetylcholine receptor peptide to prevent mice chagasic cardiac dysfunction. J
Mol Cell Cardiol 2002; 34:1645-1654.
19. Sterin-Borda L, Goin JC, Bilder CR, Iantorno G, Hernando AC, Borda E. Interaction of
human chagasic IgG with human colon muscarinic acetylcholine receptor: molecular and
functional evidence. Gut 2001; 49:699-705.
20. Mady C, Cardoso RHA, Barretto ACP, Luz PL, Bellotti G, Pileggi F. Survival and
predictors of survival in patients with congestive heart failure due to
Chagas'cardiomyopathy. Circulation 1994;90:3098-3102.
-
8/2/2019 ms - 32651
18/28
18
21. Bestetti RB. Predictors of unfavourable prognosis in chronic Chagasdisease. Trop Med
Int Health. 2001; 6:476-83.
22. de Oliveira SF, Pedrosa RC, Nascimento JH, Campos de Carvalho AC, Masuda MO.
Sera from chronic chagasic patients with complex cardiac arrhythmias depress
electrogenesis and conduction in isolated rabbit hearts. Circulation 1997; 96:2031-7.
23. Masuda MO, Levin M, De Oliveira SF, Dos Santos Costa PC, Bergami PL, Dos Santos
Almeida NA, Pedrosa RC, Ferrari I, Hoebeke J, Campos de Carvalho AC. Functionally
active cardiac antibodies in chronic Chagas' disease are specifically blocked by
Trypanosoma cruzi antigens. FASEB J. 1998; 12:1551-8.
24. Lima CJ, Limas C. b-receptor antibodies and genetics in dilated cardiomyopathy. Eur
Heart J. 1991; 12:175-7.
25. Perez Leiros C, Sterin-Borda L, Borda E, Goin JC, Hosey M. Desensitization and
sequestration of human M2 muscarinic acetylcholine receptors by autoantibodies from
patients with Chagas disease. J Biol Chem 1997; 272:12989-12993.
26. Hoebeke J. Autoimmunity against cardiovascular receptors: structural and functional
implications. Rev. Argent. Cardiol. 1995; 63:221-30.
27. Caforio ALP, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in
dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J
Heart Fail 2002; 4:411-417.
-
8/2/2019 ms - 32651
19/28
19
28. Perez Leiros C, Goren N, Sterin-Borda L, Lustig L, Borda E. Alterations in cardiac
muscarinic acetylcholine receptors in mice with autoimmune myocarditis and
assiociation with circulating muscarinic receptor-related autoantibodies. Clin Auton Res
1994; 4:249-255.
29. Acquatella H, Schiller NB, Puigbo JJ, Giordano H, Suarez JA, Casal H, Arreaza N,
Valecillos R, Hirschhaut E. M-mode and two-dimensional echocardiography in chronic
Chages' heart disease. A clinical and pathologic study. Circulation. 1980; 62: 787-99.
30. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001;
1: 92-100.
31. Silva JLL, Teixeira MM, Pedroso ERP, Rocha MOC. A leso cardaca vorticilar
associada doena de Chagas [The apical lesion of the heart in Chagasdisease]. Rev.
Med. Minas Gerais 2003; 13: 179-182.
32. Borges-Pereira J, Xavier SS, Pirmez, C. Chagas' disease in Virgem da Lapa County,
Minas Gerais State, Brazil. IV. Clinical and epidemiological aspects of the left ventricle
aneurism.Rev. Soc. Bras. Med. Trop. 1998; 31:457-463.
33. de Paola AA, Horowitz LN, Miyamoto MH, Pinheiro R, Ferreira DF, Terzian AB,
Cirenza C, Guiguer N Jr, Portugal OP. Angiographic and electrophysiologic substrates of
ventricular tachycardia in chronic Chagasic myocarditis. Am J Cardiol 1990; 65: 360-3.
34. Hagar JM, Rahimtoola SH. Chagas' heart disease in the United States. N Engl J Med
1991; 325: 763-768.
-
8/2/2019 ms - 32651
20/28
20
35. de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo EE. Ventricular
tachycardia during exercise testing as a predictor of sudden death in patients with chronic
chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J. 1995; 74: 293-5.
-
8/2/2019 ms - 32651
21/28
21
Legends of Figures
Figure 1. Scattergram showing immunoreactivity of serum anti-M2 cholinergic (A) and
anti-1 adrenergic (B) autoantibodies tested by ELISA. Dots represent the individual
optical density (OD) values for each serum sample at 1/50 dilution from 6 non-infected
(NI), 8 infected patients in indeterminate form (IND) and 52 chronic chagasic
cardiomyopathy (CCC). Dotted line shows cutoff values (mean OD values 2 SD from
NI group): anti-M2 cholinergic, 0.200, and anti-1 adrenergic, 0.100. Horizontal lines
show median OD values. *p < 0.0005 versus NI.
Figure 2. Distribution of anti-M2 cholinergic and anti-1 adrenergic cholinergic
autoantibodies in sera of chagasic patients with apical lesion. Dots represent the
individual optical density (OD) values for each serum sample at 1/50 dilution from
infected patients in the absence (30 patients) or in the presence (22 patients) of left
ventricular apical lesions. Horizontal lines show median OD values.
Figure 3. Distribution of anti-M2 cholinergic and anti-1 adrenergic autoantibodies in
sera of chagasic patients with extra systolic beats and chronotropic incompetence.
Chagasic patients were submitted to a treadmill exercise and the presence or absence of
(A) exercise-dependent ventricular arrhythmia or (B) chronotropic defect evaluated. Dots
-
8/2/2019 ms - 32651
22/28
22
represent the individual optical density (OD) values for each serum sample at 1/50
dilution. Horizontal lines show median OD values.
-
8/2/2019 ms - 32651
23/28
23
Table 1. Clinical characteristics of non-infected individuals (NI) and patients classified with
different levels of chronic chagasic cardiomyopathy (CCC).
________________________________________________________________________
NI (n=6) IND (n=8) I (n=8) II/III (n=7) IV (n=15) V (n=14)
Age 38 6.9 47 3.4 48 8.2 47 4.5 44 2.0 43 2.3
Gender 67 38 50 29 47 79
(% male)
LVEF (%) 68 6 64 4 66 2 60 3 61 2 45 3#
LVDD 48 1 48 1 49 1 47 2 50 1 62 1#(mm)
NVPB ND 1 3 725 86 840
in 24 h [0-5] [0-258] [399-5676] [18-2863] [192-3002]
Values are shown as mean SD, except for NVPB in 24h that are shown as median [25%-75% percentile].
NI: non-infected. IND: indeterminate form. LVEF: left ventricle ejection fraction. LVDD: left ventricle
diastolic diameter. NVPB: number of ventricular premature beats in 24 h. # P < 0.01 when compared to
non-infected and furthermore chagasic individuals. Non-normally distributed data were transformed before
performing ANOVA and means comparisons.
-
8/2/2019 ms - 32651
24/28
24
Table 2. Distribution of anti-M2 cholinergic and anti-1 adrenergic autoantibodies in
non-infectd individuals and infected patients
anti-M2 cholinergic anti-1 adrenergic
Groups number positive/total percentage number positive/total percentage
NI 0/6 0 0/6 0
IND 3/8 37.5* 6/8 77.1
CCC I 7/8 87.5 5/8 62.5
CCC II/III 5/7 71.4 4/7 57.1
CCC IV 14/15 93.3 13/15 86.6
CCC V 12/14 85.7 9/14 64.3
______________________________________________________________________________
Microtitre wells were coacted with 1 g peptides (anti-M2 and anti-1) and ELISA was carried
out in the presence of sera from non-infected individuals (NI), indeterminate form (IND) and
different degree of chronic chagasic cardiomyopathy (CCC I to V) infected patients. Optical
density (OD) values more than 2 SD about normal mean were taken as positive. Cutoff values
for anti-M2 cholinergic 0.200 and for anti-1 adrenergic 0.100. Prevalence values of anti-M2
cholinergic and anti-1 adrenergic autoantibodies differ with *p < 0.0005 versus CCC I to V.
-
8/2/2019 ms - 32651
25/28
25
Table 3. Lack of correlation between parameters of ventricular dysfunction and levels of
anti-adrenergic or anti-cholinergic receptor antibodies in patients with chronic chagasic
cardiomypathy (CCC).
LVEF (%) LVEDD (mm) NVPB (in 24 h)
Anti-adrenergic
antibodies
R= 0.053
p= 0.725
R= 0.052
p= 0.733
R= 0.027
p= 0.858
Anti-cholinergic
antibodies
R=0.005
p= 0.973
R= 0.120
p= 0.406
R= 0.167
p= 0.270
LVEF: left ventricle ejection fraction; LVEDD: left ventricle end-diastolic diameter; NVPB:
number of ventricular premature beats.
-
8/2/2019 ms - 32651
26/28
26
Figure 1
NI IND I II/III IV V
0.0
0.5
1.0
1.5
Chronic Chagasiccardiomyopathy
All forms
OD
(405nm)
NI IND I II/III IV V0.00
0.25
0.50
0.75
Chronic Chagasiccardiomyopathy
All forms
OD
(405n
m)
A
B
anti-M2
anti-1
-
8/2/2019 ms - 32651
27/28
27
Figure 2:
Absence Presence Absence Presence0.0
0.5
1.0
1.5
Left ventricle apical lesion
p
-
8/2/2019 ms - 32651
28/28
Figure 3:
Absence Presence Absence Presence0.0
0.5
1.0
1.5
Exercise-induced ventricular arrthymia
p